The cost-effectiveness of intensive national school-based anti-tobacco education: results from the tobacco policy model.
ABSTRACT School-based anti-tobacco education using the "social influences" model is known to reduce smoking among youth by 5-56%. Program effectiveness, however, dissipates in 1-4 years. Consequently, opinion leaders have questioned whether a more intensive national educational effort would be economically efficient. To address this question, we evaluated the cost-effectiveness of enhanced nationwide school-based anti-tobacco education relative to the status quo.
To estimate cost-effectiveness, we created the Tobacco Policy Model, a system dynamics computer simulation model. The model relies on secondary data and is designed to calculate the expected costs and public health gains of any tobacco policy or intervention over any time frame.
Over 50 years, cost-effectiveness is estimated to lie between $4,900 and $340,000 per quality-adjusted life-year (QALY), depending on the degree and longevity of program effectiveness. Assuming a 30% effectiveness that dissipates in 4 years, cost-effectiveness is $20,000/QALY. Sensitivity analysis reveals that cost-effectiveness varies with cost, survival, and quality-of-life estimates but cost-effectiveness ratios generally remain favorable.
Although not cost saving, a much more intensive school-based anti-tobacco educational effort would be an economically efficient investment for the nation.
SourceAvailable from: Niclas Olofsson[Show abstract] [Hide abstract]
ABSTRACT: To explore three school based transitions and their impact on positive self- reported- health (SRH), pre-school to elementary school (6-10 y), elementary school to junior high school (10-13y), and junior high school to upper secondary school/high school (13-16y), in a long-term longitudinal population based study.BMC Public Health 10/2014; 14(1):1045. DOI:10.1186/1471-2458-14-1045 · 2.32 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Health policy models have attracted significant offered important insights in to health trends and policy selection. More complete accounting for the cost and health implications of upstream interventions is hindered by the need to consider impact on, and interactions between, multiple comorbidities. Within this paper, we explore several distinct approaches for representing comorbidities, some of them at the aggregate level, and some of them at the individual level. All of these representations have the virtue of being declarative, in that they allow the user to focus on what is to be characterized, rather than how it is to be implemented. Our exploration suggests that while several aggregate representations of comorbidities are possible, they suffer from a variety of shortcomings, ranging from low fidelity to combinatorial blowup. While individual-level representations impose a heavy performance load, greater difficulties in calibration and less rapid analysis, such representations do offer greater transparency, modifiability, scalability, and modularity, and ease of representing transmission and influence networks. With much to recommend each approach, further research is needed to shed additional light on the tradeoffs and identify situations where one representation is preferable to another.
[Show abstract] [Hide abstract]
ABSTRACT: A modelling project involved system dynamics simulation of chronic cardiac disease in Bulgaria, examining the dynamic behaviour of a cardiac drug molecule in the market. The system dynamics model was calibrated using market data sourced from the Bulgarian National Health Care Fund, the Bulgarian Generic Pharmaceutical Association and a market research firm. The main results of the study showed that the timing of access to market was a critical driver in reducing prices and providing wider, as well as more affordable, access for patients to medicinal therapy. Our findings indicate that healthcare authorities may obtain savings while, at the same time, they may provide conditions for more patients to be treated depending on the timing of access to market of new generic drugs.Journal of the Operational Research Society 01/2013; 64(12). DOI:10.1057/jors.2012.150 · 0.91 Impact Factor